U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07889999) titled 'Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty' on Oct. 08.
Brief Summary: This study will look at the health characteristics of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) in Kazakhstan. Researchers want to better understand how this liver condition appears in people in Kazakhstan and how it is managed in everyday medical care.
About 420 adults with MASLD will take part. Researchers will collect information from their medical records, laboratory tests, liver imaging, and questionnaires.
A smaller group of about 65 participants in Almaty who we...